地球／自然／いきもの
について、話し合って
みませんか。
　園芸や身近な自然のこと、自然観察会などのイベント情報、「あそこで珍しいものを見ました！」、
そして自然からの贈り物「健康によい自然療法」「ハーブやアロマテラピー」、今や人間の伴侶とも
いえる「ペット」に関する話題など関連する話題なら、どのようなものでもお待ちしています。

[記事表示に戻る] [ツリートップの表示に戻る] 
◇-mvOOpBGnpNDZmvCL-Randall(1/27-10:35)No.36206
トップに戻る
36206mvOOpBGnpNDZmvCLRandall E-mail URL1/27-10:35

I'm originally from Dublin but now live in Edinburgh https://www.western.ac.th/westernnew/pharmacy/index.php/organic-india-ashwagandha-vitamin-shoppe-tezr organic india ashwagandha vitamin shoppe The debate has sprung from a clinical trial that aims to see whether low-dose stavudine, or d4T, is as effective as tenofovir, or TDF, one of the antiretrovirals (ARVs) currently recommended for first-line HIV treatment by the World Health Organisation (WHO). d4T was long used as the primary first-line therapy but harsh side effects, including neuropathy (nerve damage) and lipodystrophy (abnormal, sometimes disfiguring, fat distribution), led the WHO to recommend against its use in 2011.It suggested that TDF or zidovudine (AZT) be used instead. But both drugs are relatively expensive: according to the health advocacy organisation, M辿decins Sans Fronti竪res (MSF), d4T is available for as little as $20 (R204) a patient a year, compared with $75 (R764) a patient a year for AZT and $57 (R581) a patient a year for TDF.ツ